No C 11/10 Official Journal of the European Communities 17. 1. 91 
II 
(Preparatory Acts) 
COMMISSION 
Amended proposal for a Council Decision adopting a specific research and technological devel­
opment programme in the field of biomedicine and health (1990 to 1994) (') 
COM(90) 676 final — SYN 267 
(Submitted by the Commission pursuant to Article 149(3) of the EEC Treaty on 14 December 
1990) 
(91/C 11/04) 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty establishing the European 
Economic Community, and in particular Article 130q (2) 
thereof, 
Having regard to the proposal from the Commission, 
In cooperation with the European Parliament, 
Having regard to the opinion of the Economic and 
Social Committee, 
Whereas, by its Decision 90/221/Euratom, EEC (2), the 
Council adopted a third framework programme for 
Community activities in the field of research and techno­
logical development (1990 to 1994), specifying inter alia 
the activities to be pursued for contributing to the devel­
opment of the European potential for understanding and 
exploiting the properties and structures of living matter; 
whereas this Decision should be taken in the light of the 
grounds set out in the preamble to that Decision; 
Whereas Article 130k of the Treaty stipulates that the 
framework programme shall be implemented through 
specific programmes developed within each activity; 
Whereas an estimate should be made of the amount of 
Community financial resources needed to carry out 
this specific programme; whereas the definitive amounts will be fixed by the budgetary authority in line 
with the financial perspectives covering the period 1988 
to 1992 included in the interinstitutional Agreement of 
29 June 1988 (J) and with any future financial 
perspectives covering the period 1993 to 1994; 
Whereas fundamental research must be specifically 
encouraged Community-wide in each of the strategic 
research sectors of the framework programme; 
Whereas, in addition to the specific programme on 
human capital and mobility, training of researchers in 
each of the strategic research sectors of the framework 
programme must be ensured; 
Whereas the social and human impact of the programme 
must be assessed by an independent panel and tech­
nology and risk assessment be undertaken, particularly in 
the field of bioethics; 
Whereas, pursuant to Article 4 and Annex I of Decision 
90/221/Euratom, EEC, the funds estimated as necessary 
for the whole of the framework programme include an 
amount of ECU 57 million for the centralized dissemi­
nation and exploitation of results, to be divided up in 
proportion to the amount envisaged for each activity; 
whereas in view of the importance of this specific 
programme within the 'Life Sciences and Technologies' 
action the estimate of the financial resources needed by 
this programme is to be reduced by ECU 1,33 million, 
which amount is to be allocated to the said centralized 
activities, in order to comply with the second sentence of 
Article 130p (2) of the Treaty; 
O OJ No C 174, 16. 7. 1990, p. 65. 
(2) OJ No L 117, 8. 5. 1990, p. 28. O OJ No L 185, 15. 7. 1988, p. 33. 
17. 1.91 Official Journal of the European Communities NoC 11/11 
Whereas this programme must be implemented by the 
Commission; whereas to help accomplish this, the 
Member States are bound, pursuant to Article 5 of the 
Treaty, to facilitate the achievement of its tasks where 
necessary, notably within a committee; 
Whereas this programme must be implemented essen­
tially by the selection of research and development 
projects to enable them to benefit from Community 
participation; whereas the Commission should encourage 
the submission of such projects by the usual means of 
publishing calls for proposals in the Official Journal of the 
European Communities; whereas an exceptional 
procedure should also be devised so as to come into 
effect between calls for proposals to maintain a degree of 
flexibility enabling the Commission, in the face of the 
continuous evolution and gradual acceleration of techno­
logical progress, also to take into consideration spon­
taneous proposals consistent with the objectives of the 
programme; 
Whereas support for the international competitiveness of 
European industry, through Community research and 
technological development programmes, is linked with 
the Community's external relations policy based on the 
principle of 'the global equilibrium of opportunities', and 
that it is also in the light of this policy that participation 
of European companies owned by citizens of 
non-Community countries must be considered; 
Whereas the projects to be carried out under the 
programme must be selected with special attention to the 
principle of economic and social cohesion in the 
Community, to the transnational nature of the projects 
and to the support to be given to small and 
medium-sized enterprises; 
Whereas it is only in the light of experience gathered in 
the course of development of this programme that the 
Commission will be able to propose and the Council to 
adopt supplementary programmes by having recourse to 
the means provided for in Articles 1301, 130m or 130o of 
the Treaty, if they contribute to the achievement of the 
programme's objectives, in accordance with the option 
made available by Article 2 (2) of Decision 
90/221/Euratom, EEC; 
Whereas, in accordance with Article 130g of the Treaty, 
the Community's activities aimed at strengthening the 
scientific and technological basis of European industry 
and encouraging it to become more competitive include 
promoting cooperation on research and technological 
development with third countries and international 
organizations; whereas such cooperation may prove 
particularly beneficial to the development of this 
programme; Whereas it is necessary, as Annex II to Decision 
90/221/Euratom, EEC, provides, to contribute to 
improving the efficacy of medical and health research 
and development in the Member States, in particular by 
better coordination of the Member States' research and 
development activities and application of the results 
through Community cooperation and a pooling of 
resources; 
Whereas the Scientific and Technical Research 
Committee (Crest) has been consulted, 
HAS ADOPTED THIS DECISION: 
Article 1 
A specific research and technological development 
programme for the European Economic Community in 
the field of biomedicine and health, as defined in Annex 
I, is hereby adopted for the period from the date of 
publication of this Decision in the Official Journal of the 
European Communities to 31 December 1994. 
Article 2 
1. The Community funds estimated as necessary for 
the execution of the programme under this Decision 
amount to ECU 133 million. From these funds, an 
amount of ECU 1,33 million is drawn for the centralized 
action of dissemination and exploitation of results. The 
amount thus reduced to ECU 131,67 million includes 
staff costs which may not exceed 4 %. An indicative 
breakdown of expenditure is set out in Annex II. 
2. Should the Council take a decision in implemen­
tation of Article 1 (4) of Decision 90/221/Euratom, 
EEC, this Decision shall be adapted to take account of 
the abovementioned decision. 
3. The budgetary authority shall decide on the appro­
priations available for each financial year. 
Article 3 
Rules for the implementation of the programme are set 
out in Annex III. 
Article 4 
The rate of the Community financial contribution shall 
be laid down in accordance with Annex IV to Decision 
90/221/Euratom, EEC. 
NoC 11/12 Official Journal of the European Communities 17. 1.91 
Article 5 
1. During 1992 the Commission shall review the 
programme and address a report on the results of the 
review to the Council and the European Parliament, 
together with proposals for any necessary changes. 
2. At the end of the programme, the Commission shall 
assess the results obtained. It shall address a report 
thereon to the Council and the European Parliament. 
3. The reports shall be drawn up having regard to the 
objectives set out in Annex I to this Decision and 
in accordance with Article 2 (4) of Decision 
90/221/Euratom, EEC. These reports shall assess the 
coherence of the programme's measurable implemen­
tation with the six major concerns set out in Annex II to 
Council Decision 90/221/Euratom, EEC. 
Article 6 
1. The Commission shall be responsible for the 
execution of the programme. It shall be assisted by a 
committee, hereinafter referred to as 'the committee', 
composed of representatives of the Member States and 
chaired by a representative of the Commission. 
2. The contracts concluded by the Commission shall 
govern the rights and obligations of each party, 
including the procedures for disseminating, protecting 
and exploiting the research results, in accordance with 
the arrangements adopted pursuant to the second 
paragraph of Article 130k of the Treaty and, where 
appropriate, procedures for training and evaluation. 
3. A work programme shall be drawn up at the start 
of the programme and shall be regularly revised. It shall 
set out the detailed objectives and types of projects to be 
undertaken, and the financial arrangements to be made 
for them. The Commission shall make calls for proposals 
for projects on the basis of the work programmes. 
Article 7 
1. In the cases envisaged in Article 8 (1), the 
Commission representative shall submit to the committee 
a draft of the measures to be taken. The committee shall 
deliver its opinion on the draft within a time limit which 
the chairman may set according to the urgency of the 
matter. The opinion shall be delivered by qualified 
majority as provided for in Article 148 (2) of the Treaty 
for the adoption of decisions which the Council is called 
upon to make on a proposal from the Commission. 
"When voting takes place in the committee, the votes of 
the representatives of the Member States shall be 
weighted as specified in the abovementioned Article. The 
chairman shall not take part in the voting. 2. The Commission shall adopt the measures 
envisaged where they are in accordance with the 
committee's opinion. 
3. If the measures envisaged are not in accordance 
with the committee's opinion, or if no opinion is 
delivered, the Commission shall forthwith submit to the 
Council a proposal relating to measures to be taken. The 
Council shall act by a qualified majority. 
4. If the Council has not acted within one month of 
submission of the proposal, the proposed measures shall 
be adopted by the Commission. 
Article 8 
1. The procedure laid down in Article 7 shall apply 
to: 
— preparation and updating of the work programmes 
referred to in Article 6 (3), 
— evaluation of the projects, referred to in point 2 of 
Annex III, as well as the estimated amount of the 
Community's financial contribution, when these 
projects are submitted through the ordinary 
procedure referred to in point 4 of Annex III and the 
abovementioned amount is more than ECU 5 million, 
— evaluation of all projects submitted through the 
exceptional procedure referred to in point 4 of Annex 
III, as well as the estimated amount of the 
Community's financial contribution, 
— measures for evaluating the programme. 
2. The Commission may consult the Committee on 
any matter falling within the scope of the programme. 
3 The Commission shall inform the Committee with 
regard to: 
— the progress of the programme, 
— planned calls for proposals, referred to in Article 
6 (3), 
— projects, referred to in point 2 of Annex III, 
submitted through the ordinary procedure, for which 
the Community contribution is less than ECU 
5 million, and the results of their evaluation, 
— accompanying measures, referred to in point 2 of 
Annex III, 
17. 1.91 Official Journal of the European Communities NoC 11/13 
— concerted actions, referred to in point 2 of Annex HI. 
Article 9 
In implementing this programme, supplementary 
programmes within the meaning of Article 1301, partici­
pation within the meaning of Article 130m and joint 
undertakings or any other structures within the meaning 
of Article 130o of the Treaty may also be decided on as 
the need arises. 
Article 10 
Where cooperation with third countries and international 
organizations aiming at achieving the objectives of this 
programme requires legal undertakings between the 
Community and the third parties concerned, the 
Commission shall be authorized to negotiate, in 
accordance with Article 130n of the Treaty, international 
agreements laying down the terms of such cooperation. Priority will be given to cooperation with EFTA 
countries and European countries not members of the 
European Community, in accordance, where appro­
priate, with the guidelines drawn up between the Council 
and the European Parliament during the conciliation 
procedure on the third framework programme. 
The negotiations for such international agreements may 
only be initiated with third countries who are already 
signatories of an agreement with the Community which 
explicitly cites research and technological development 
or scientific progress as one of the objectives of 
cooperation. 
Decisions on the conclusion of such international 
agreements shall be adopted in accordance with the 
procedure referred to in Article 130q (2) of the Treaty. 
Article 11 
This Decision is addressed to the Member States. 
ANNEX I 
Scientific and technical objectives and content 
This specific programme fully reflects the approach embodied in the third framework programme in terms 
of the scientific and technical goals and the underlying aims which it pursues. 
Paragraph 4C of Annex II of the framework programme forms an integral part of the present specific 
programme. 
Close coordination will be maintained with other relevant research programmes, including 'Biotechnology', 
'Life Sciences and Technologies for Developing Countries', 'Telematics Systems — Health Care', 'Medical 
Research' under the European Coal and Steel Community Treaty, and also the 'Europe against Cancer' 
programme. 
The principle of subsidiarity will be applied to the maximum. Harmonization of approaches and methodo­
logies used in different national programmes will be encouraged. The projects within the programme will 
have a European dimension based on research networks. Their main criteria will be quality and 
additionality. Strengthening of networks, particularly by the establishment of 'European Laboratories 
Without Walls', will aim at the development of specific and competitive subject areas. Mobility of research 
workers between participating laboratories will be encouraged, including for short periods of time. 
Harmonized methods, specific to the relevant protocols, will ensure that the data resulting from the 
projects carried out throughout the Community can be analysed and exploited anywhere in the 
Community. Coordination with national activities will ensure effective use of resources. 
The fundamental role of basic research in underpinning the work of the programme is recognized. Prenor-
mative research will be developed whenever needed for the completion of the internal market, in respect of 
serving patients' needs. 
NoC 11/14 Official Journal of the European Communities 17. 1.91 
The following presents an analytical description of the content of the programme, based on and taking 
account of the above elements. 
Area 1: Development of coordinated research on prevention, care and health systems 
This area covers the harmonization of methodologies and protocols in epidemiological, biological, clinical 
and technological research. The key targets will be: 
Precompetitive drug-testing and research into the monitoring and surveillance of drug-prescribing 
practices, patient compliance and the incidence of adverse drug reactions will be carried out, based on 
clinical and epidemiological data collected through coordinated networks, and with a view to an improved 
harmonization of norms, parameters and guidelines. 
Risk factors relating to occupational health, including dangerous substances and biological agents, will be 
studied with the aim of their identification, and of risk prevention and of early detection of disease. Among 
the subject fields will be information methods for workers about safety and cost-effective management of 
screening systems. Research related to the genetic screening of workers for apparent predispositions to 
occupational diseases and workplace hazards, and which implies those workers' participation, will not be 
conducted without their consent. 
Enhancement and application of biomedical technology to medical and health care will be directed towards 
the development of coherent systems and procedures for diagnosis, therapy, prevention, care and rehabili­
tation. Coordination of basic research (modelling) in biomedical technology will be aimed at fundamental 
insight into failing human functions and on the characteristics of biomaterials. Applied technological 
research will be aimed at artificial systems to restore failing human functions and alleviate handicaps as 
completely as possible. 
Lastly, support must be given in these different fields to multicentre studies between countries to facilitate 
the granting of patents, epidemiological studies and authorizations for the marketing of new medicinal 
products. 
Harmonization of protocols and approaches in health services will be emphasized, particularly with Europe 
1992 in view. Research will be carried out into the financing of health care, the management of the health 
care workforce, and health care systems. The methodology of research into prevention, therapy and reha­
bilitation will also be studied. 
Area 2: Major health problems and diseases of great socio-economic impact 
Major health problems and economically and socially significant disease groupings will be considered, in 
particular the following: 
AIDS 
The research will take into account the activities already developed by the Community and will be spread 
over five main sectors: 
— disease prevention — concentrating on specific epidemiological projects, studies of primary and 
secondary prevention, assessment of preventive strategies, behavioural research and forecasting, 
17. 1.91 Official Journal of the European Communities NoC 11/15 
— fundamental research — concentrating on AIDS viruses, host response, pathogenesis and experimental 
mode}s, 
— clinical research — concentrating on clinical trials, clinical manifestations, support of clinical centres 
and national coordination, 
— the development of a 'European Vaccine against AIDS' (EVA) will be actively pursued. A centralized 
facility will work in collaboration with industrial and academic laboratories to produce antigens, sera, 
cells and other materials, 
— testing methods of 'Antiviral Drugs in AIDS Management' (ADAM) will be developed. Primary 
screening capacity will be increased by introducing additional primary screening methods. 
In this specific area collaboration with other European Community actions, including the specific 
programme on 'Life Sciences and Technologies for Developing Countries', will receive particular attention. 
Cancer 
Epidemiology and fundamental research on genomic and phenotypic changes in cancer cells (invasion and 
metastasis) and immune surveillance will be extended. Particular attention will be paid to research into 
oncogenes and antioncogenes. Priority support activities will include the improvement of European tumour 
cell and tissue bank resources, and the development of the scientific basis for common guidelines for anti­
cancer drug screening. 
Research will concentrate on improved methodologies involving differing combinations of surgery, 
radiotherapy, chemotherapy and immunotherapy, and their subsequent harmonization with associated local 
and general approaches. 
Research will also be carried out on the links between environmental factors and the incidence of cancer, 
with the aim of developing preventive approaches, in coordination with the research programme on the 
environment. 
In conjunction with the 'Europe against Cancer' programme, particular attention will be paid to research in 
the area of paediatric oncology. 
Cardiovascular disease 
The various forms of heart and circulatory disease will be studied, focusing on research where coherent 
broadly-based clinical and epidemiological surveys are most useful; this will include correlation between 
genetic factors, lifestyle, nutrition, and the incidence and development of cardiovascular disturbances, the 
effects of prophylactic and therapeutic measures, the development of new regimens for treatment including 
non-invasive methods of diagnosis, and the testing of drugs. 
Mental illness and neurological disease 
Multidisciplinary approaches to the study of aetiological factors and predisposing conditions will be 
developed in a range of psychosocial environments. The aim of such studies will be to improve under­
standing of the causes of mental illness and also the evolution from pathology to disability and social 
disadvantage, and to develop new methods of prevention and care. 
A global approach to the study of central nervous system malfunctioning common to pathological and 
physiopathological conditions will be pursued, to improve understanding of aetiopathogenic mechanisms. 
NoC 11/16 Official Journal of the European Communities 17. 1.91 
Specific studies will be carried out in the areas of enzymology, neuroendocrinology and genetics. 
Particular attention will also be paid to the part played by mental processes in the development of diseases 
such as cancer, AIDS or cardiovascular disorders. 
Ageing, age-related health problems and handicaps 
Research on perinatal illnesses (including the study of the social and economic impact of prenatal 
diagnosis) and paediatric illnesses and on the effectiveness of prophylactic and therapeutic measures will be 
carried out. 
The overall target for research in the field of ageing will be directed towards prevention of and coping 
with dependency. A concerted approach to the study of ageing will be pursued in order to identify essential 
elements in the maintenance of the quality of life in the aged, in preventing or delaying the functional 
decline of the individual, and in reducing costs to society. Emphasis will be placed on longitudinal studies 
on ageing in different cultural settings, and on specific pathologies relating to ageing such as senile 
dementia, osteoporosis and disorders of the immune system. Special attention will be given to the effects of 
the environment on health, especially on people in the more vulnerable age groups; this will be pursued in 
close liaison with research on environmental protection. 
Studies will be carried out on methods of improving organ transplants. 
Area 3: Human genome analysis 
This research will be developed towards the completion and the integration of the genetic and physical 
maps. In addition, the study of the genetic basis for biological functions will be pursued, as well as the 
setting up of a coordinating mechanism to sequence a portion of the genome of major biological interest 
(e.g. the portion coding for the human lymphocyte antigen system). 
Emphasis will be placed on medical applications which contribute to the wellbeing of patients: in coordi­
nation with other elements of the research programme in biomedicine and health, to ensure that the 
advances in the understanding of genetics are used to enhance human health; in particular, on under­
standing the genetic component of multifactorial conditions such as Alzheimer's disease, and on developing 
methods intended to improve therapies. 
Links will be maintained with appropriate international organizations or forums (e.g. HUGO, the Human 
Genome Organization), as well as with research actions in non-Member States using similar or 
complementary approaches. The Community programme is characterized by its emphasis on gene mapping 
and on the use of information resulting from the analysis of other species' genomes. It is therefore 
important that the research programme in biomedicine and health should link closely with relevant acti­
vities elsewhere in the framework programme. 
Particular attention and caution will be given to the ethical, social and legal aspects of this work, especially 
to those which may be linked to possible misuses of research findings. No research modifying, or seeking 
to modify, the genetic constitution of human beings by alteration of germ cells or of any stage of embryo 
development which may make these alterations hereditary will be carried out under this programme. 
However, the results of this research must enable the genetic data of the donors required for transplants to 
be established at any time. 
17. 1.91 Official Journal of the European Communities NoC 11/17 
Area 4: Research on Biomedical ethics 
Studies will deal with: 
— the compilation of current legislation on bioethics and current projects, 
— the organization of meetings of experts in the field of bioethics with a view to drawing up Community 
positions, 
— the evaluation of the social impact of the programme, as well as any technological risks which may be 
associated with it, 
— the assessment of the bioethical aspects of the various research programmes in the framework 
programme of Community activities and research. 
Preparatory studies will be undertaken with a view to the setting up of a European ethical observatory in 
conjunction with the European institutions and organizations. 
ANNEX II 
Indicative breakdown of expenditures 
for the period 1990 to 1994 
(in %) 
Area 1: Development of coordinated research on prevention, care and 
health systems 20-25 
Area 2: Major health problems and diseases of great socio-economic 
impact, with AIDS receiving 50 °/o of the sum for Area 2 55-60 
Area 3: Human genome analysis 20-25 
Area 4: Research on Biomedical ethics: 5 % of the total for Areas 1, 2 
and 3. 
The breakdown between different areas does not exclude the possibility that projects could cover several 
areas. 
1. An amount equivalent to 10 % of the total shall be used for projects encouraging fundamental research, 
which should be clearly identified. 
2. An amount equivalent to 5 % of the total shall be devoted to projects encouraging the training of 
researchers in the field covered by this specific programme. 
No C 11/18 Official Journal of the European Communities 17. 1. 91 
ANNEX III 
Rules for implementing the programme and activities for dissemination and exploitation of the 
results 
1. The Commission shall implement the programme on the basis of the scientific and technical content 
described in Annex I. 
2. The rules for implementing the programme, referred to in Article 3, comprise research and techno­
logical development projects, accompanying measures and concerted actions. 
The projects shall be the subject of shared-cost research and technological development contracts. 
The accompanying measures consist of applying the means to ensure proper technical execution, 
management and evaluation of the programme, as well as adequate dissemination and accessibility of 
the results, and coordination, training and consciousness-raising of the participants in the programme. 
The concerted actions are those defined in Article 92 of the Financial Regulation. 
3. The participants in the projects must be natural or legal persons established in the Community, such as 
universities, research organizations and industrial firms, including small and medium-sized enterprises, 
or associations thereof, in particular European Economic Interest Groupings (EEIGs). 
Natural or legal persons established in countries which have concluded cooperation agreements on 
scientific and technical research with the Community may, on the principle of mutual benefit, participate 
in the projects undertaken in the framework of this programme. Such contracting parties will not benefit 
from Community financing under the framework programme. They will contribute to the general 
administrative costs. 
4. The choice of projects shall be carried out according to the following order of priority, the first method 
being the rule, the second the exception. 
The participants in the projects shall be selected on the basis of the ordinary procedure of calls for 
proposals referred to in Article 6 (4) and published in the Official Journal of the European Communities. 
Where other criteria of scientific excellence are satisfied, and in accordance with the guidelines agreed 
between Council and the European Parliament, in the case of a number of project proposals of equal 
scientific value, preference shall be given: 
(i) to project proposals whose implementation involves project participants in less-developed regions 
and/or regions in industrial decline as defined by Articles 8 and 9 of Council Regulation EEC 
No 2052/88; 
(ii) to project proposals involving small and medium-sized entreprises or an association of such enter­
prises. 
The Commission shall determine in each case whether the management of the programme, or parts 
thereof, can be undertaken by organizations or institutions outside the Commission, without delegation 
of its decision-taking powers. 
The Commission may also accept proposals, according to an exceptional procedure and under the 
conditions mentioned below, when they make a particularly promising and significant contribution as 
regards the originality of the theme proposed, the novelty of the scientific and technical approach and 
the methodology of execution, also taking into account the particular nature of the proposers. 
17. 1. 91 Official Journal of the European Communities No C 11/19 
A favourable technical evaluation of such proposals shall not by itself be a sufficient justification for 
accepting a project; this exceptional procedure may only apply after verification that the nature of the 
project, as defined above, does not justify the use of the normal procedure for calls for proposals. 
The exceptional procedure shall come into effect after the first call for proposals and must be completed 
before the ordinary procedure in such a way that the available amount for the Community's financial 
participation in projects retained by the ordinary procedure can be determined precisely. The closing 
date for the exceptional procedure shall be published each year in the Official Journal of the European 
Communities. 
When it submits the preliminary draft budget the Commission shall inform the budgetary authority 
whether the appropriations approved in the budget of the previous year have also financed projects 
retained by the exceptional procedure and the amounts allocated. Should these projects cover several 
programmes, it shall state the type of committee which assisted it. 
The amount of the financial participation of the Community for all the projects retained by the excep­
tional procedure will be decided each year, in relation to the projects selected according to particularly 
strict criteria of excellence. In any case this amount may not exceed 10 %; it may be revised each year 
in the light of experience. 
The Commission shall draw up a vade mecum setting out all the rules applicable to this exceptional 
procedure in order to guarantee full transparency. 
5. The projects must involve at least two mutually independent partners established in different Member 
States. 
6. The Commission may encourage the participants to form a European Economic Interest Grouping 
(EEIG) or make other arrangements for carrying out projects, such as those on a large scale, permitting 
decentralized management adapted to the specific requirements of the project. 
7. The knowledge acquired during the course of the projects shall be disseminated on the one hand within 
the specific programme and on the other hand by means of a centralized activity, pursuant to the 
decision referred to in the third paragraph of Article 4 in Decision 90/221 /Euratom, EEC. 
Proposal for a Council Decision concerning the conclusion of the amendment to the Montreal 
Protocol on substances that deplete the ozone layer as adopted in June 1990 in London by the 
Parties to the Protocol 
COM(90) 589 final 
(Submitted by the Commission on 20 December 1990) 
(91/C 11/05) 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty establishing the European 
Economic Community, and in particular Article 130s 
thereof, 
Having regard to the proposal from the Commission, Having regard to the opinion of the European 
Parliament, 
Having regard to the opinion of the Social and 
Economic Committee, 
Whereas the Community together with all of its Member 
States signed the Vienna Convention for the protection 
of the ozone layer;